Reassessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Long Term Returns And A High Current P/E Ratio

Why Amneal Pharmaceuticals Is On Investors’ Radar Today

Amneal Pharmaceuticals (AMRX) has caught fresh attention after a period where the share price has been mixed, with a small 1 day gain, weaker recent month performance, and a stronger past 3 months and 1 year.

For investors, this creates a chance to reassess how the company’s current US$13.25 share price lines up with its recent business results, including revenue of US$3,018.76m and net income of US$72.06m, along with its value score of 3.

See our latest analysis for Amneal Pharmaceuticals.

Short term, Amneal’s share price has pulled back, with a 30 day share price return showing an 8.75% decline. Longer term momentum looks stronger, supported by a 1 year total shareholder return of 52.30% and a very large 3 year total shareholder return close to 8x.

If this kind of move has you looking beyond a single name, it could be a good moment to scan the broader healthcare opportunity set through our curated list of 32 healthcare AI stocks.

With Amneal trading at US$13.25 against analyst targets of US$16.80 and an intrinsic value suggesting a possible discount, the key question is simple: is this genuine value or is the market already pricing in future growth?

Most Popular Narrative: 19.2% Undervalued

At a last close of $13.25 versus a narrative fair value of $16.40, Amneal is framed as undervalued, with the gap built on medium term earnings power.

The recent debt refinancing, substantial reduction in annual interest expense, and anticipated tax benefits (from immediate R&D expensing) give Amneal greater financial flexibility to reinvest in high-growth areas and pursue vertical integration of biosimilars, which could further enhance future earnings and free cash flow.

Read the complete narrative.

Want to see what is behind that higher earnings story and fair value? Revenue assumptions shift, margins reset, and the future profit multiple jumps. The full narrative walks through how those moving pieces line up to reach $16.40.

Result: Fair Value of $16.40 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, that higher earnings story can quickly look different if U.S. generics pricing pressure intensifies or if high debt and regulatory costs squeeze margins more than expected.

Find out about the key risks to this Amneal Pharmaceuticals narrative.

Another Angle On Valuation

The fair value story so far leans on future earnings power and a rich P/E in the years ahead. Yet on today’s numbers, Amneal trades on a P/E of 57.9x versus 18.8x for the wider US Pharmaceuticals group and 26.6x for peers, while our fair ratio points to 19.8x.

That gap suggests the current price already bakes in a lot of optimism, at least on this metric, even as other models flag undervaluation. As an investor, which do you weigh more: the long term narrative or the high multiple you are paying today?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mix of opportunity and caution here feels finely balanced, now is the time to look through the numbers yourself and decide where you stand. You can start with 4 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Amneal has sparked your interest, do not stop here. The real edge comes from comparing a few high quality ideas side by side before you commit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com